deltatrials
Terminated NA INTERVENTIONAL 1-arm NCT01649791

Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia

A Pilot Study of Lenalidomide as a Chemopreventive Agent for Patients With High-Risk, Early Stage B-Chronic Lymphocytic Leukemia (CLL)

Sponsor: Celgene Corporation

Conditions B-cell Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemia Stage 0 Chronic Lymphocytic Leukemia Stage I Chronic Lymphocytic Leukemia Stage II Chronic Lymphocytic Leukemia
Interventions bone marrow aspiration flow cytometry laboratory biomarker analysis lenalidomide lymph node biopsy pharmacological study
Updated 7 times since 2017 Last updated: May 26, 2016 Started: Jan 31, 2010 Primary completion: May 31, 2012 Completion: Oct 31, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Celgene Corporation

More terminations from Celgene Corporation

Other B-cell Chronic Lymphocytic Leukemia trials with similar outcome

Browse all B-cell Chronic Lymphocytic Leukemia trials

A NA clinical study on B-cell Chronic Lymphocytic Leukemia and Chronic Lymphocytic Leukemia, this trial is terminated or withdrawn. The trial is conducted by Celgene Corporation and has accumulated 7 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotTerminated~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated NA

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated NA

  3. Dec 2021 — Jul 2024 [monthly]

    Terminated NA

  4. Jan 2021 — Dec 2021 [monthly]

    Terminated NA

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated NA

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Terminated NA

  2. Jan 2017 — Feb 2017 [monthly]

    Terminated NA

    First recorded

Jan 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Celgene Corporation
  • National Cancer Institute (NCI)
  • Roswell Park Cancer Institute
Data source: Roswell Park Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations